Tracking Baker Brothers Portfolio: Q1 2026 Update
Kodiak Sciences Inc KOD
$41.58
▼ -2.16%
($-0.92)
🔥 High Short Interest
🎢 High Beta
🗓️ Earnings Next Week
Open
$42.45
Prev Close
$42.50
Day Range
$40.35 – $42.93
52W Range
$6.21 – $47.84
Market Cap
$2.60B
Beta
2.19
EPS (TTM)
$-4.17
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-10-04 |
| Shares Out. | 62,580,000 |
| Website | kodiak.com/ ↗ |
| Phone | 13026365400 |
| Employees | 124 |
| Net Income | -$58.2M |
| Free Cash Flow | -$148.1M |
| Total Assets | $306.0M |
| Total Liabilities | $193.9M |
| Equity | $112.1M |
About Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Kodiak Sciences Inc is a publicly traded company under the ticker symbol KOD on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)